Author:
Abraham Jacob,McCann Patrick J.,Guglin Maya E.,Bhimaraj Arvind,Benjamin Terrie-Ann S.,Robinson Monique R.,Jonsson Orvar T.,Feitell Scott C.,Bhatt Kunjan A.,Bennett Mosi K.,Heywood J.T.,
Abstract
Abstract
Purpose of Review
Heart failure (HF) management guided by hemodynamics obtained from an implantable pulmonary artery pressure (PAP) sensor (CardioMEMS) improves symptoms and reduces HF hospitalizations (HFH). This paper reviews the theoretical basis of pulmonary vascular physiology, summarizes recently published data about CardioMEMS, and provides practical guidelines for patient selection and management.
Recent Findings
Compared to patients managed by standard care, HF patients randomized to PAP-guided treatment have a higher frequency of medication adjustments, resulting in lower PAP and fewer HFH. Real-world analyses further support associations between implant of the CardioMEMS sensor with reductions in PAP, hospitalizations, and mortality.
Summary
Implantable, wireless hemodynamic sensor technology is a promising remote monitoring platform for chronic HF. A phased approach using a treatment algorithm may improve the efficiency and effectiveness of pressure-guided therapy.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献